News articles about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.4740737648707 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Zynerba Pharmaceuticals (ZYNE) traded down 4.82% during trading on Monday, reaching $5.93. 377,770 shares of the company were exchanged. Zynerba Pharmaceuticals has a one year low of $5.82 and a one year high of $23.57. The stock has a 50-day moving average price of $6.28 and a 200-day moving average price of $6.28. The stock’s market capitalization is $78.61 million.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). Analysts forecast that Zynerba Pharmaceuticals will post ($2.42) EPS for the current year.

A number of equities analysts have recently commented on ZYNE shares. Jefferies Group LLC reiterated a “buy” rating and set a $32.00 price target on shares of Zynerba Pharmaceuticals in a report on Sunday, July 9th. Maxim Group set a $32.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, June 26th. Roth Capital set a $30.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 10th. Cantor Fitzgerald set a $28.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, June 8th. Finally, HC Wainwright set a $30.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $12.67.

WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Zynerba Pharmaceuticals (ZYNE) Share Price” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/25/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-zynerba-pharmaceuticals-zyne-share-price.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Insider Buying and Selling by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.